CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of CanSino Biologics Inc. (the "**Company**") dated September 26, 2025, in relation to, among other things, (i) the proposed adoption of the 2025 H Share Option Scheme; and (ii) the grant of H Share Options under the 2025 H Share Option Scheme (the "**Announcement**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to clarify that the grant of H Share Options under the 2025 H Share Option Scheme is conditional upon the 2025 H Share Option Scheme becoming effective, which is subject to Shareholders' approval at the EGM.

A circular of the Company containing, among other things, (i) further details of the 2025 H Share Option Scheme; and (ii) a notice convening the EGM is expected to be despatched to the Shareholders in due course.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, September 30, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.